|
|||||
|
|
A phase I clinical trial of navitoclax,a targeted high-affinity Bcl-2 family inhibitor,in combination with gemcitabine in patients with solid tumors |
|
| Authors: | James M. Cleary Caio Max S. Rocha Lima Herbert I. Hurwitz Alberto J. Montero Catherine Franklin Jianning Yang Alison Graham Todd Busman Mack Mabry Kyle Holen Geoffrey I. Shapiro Hope Uronis |
| Affiliation: | 1. Department of Medical Oncology, Dana-Farber Cancer Institute and Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA 2. University of Miami Sylvester Comprehensive Cancer Center, Miami, FL, USA 3. Division of Medical Oncology, Duke University Medical Center, Durham, NC, USA 4. Cleveland Clinic Taussig Cancer Institute, Department of Solid Tumor Oncology, Cleveland, OH, USA 5. AbbVie Inc, North Chicago, IL, USA 6. Early Drug Development Center, Dana-Farber Cancer Institute, 450 Brookline Avenue, Mayer 446, Boston, MA, 02215, USA |
| Abstract: | |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ | |